The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis
| Autor: | Ximing Xu, Wei Ge, Jinju Lei, Huilin Xu, Dedong Cao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Solid cancer Immune checkpoint inhibitors medicine.medical_treatment Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 survival Immune system Meta-analysis Internal medicine Medicine Biomarker (medicine) biomarker immune-related adverse events immunotherapy business Adverse effect Meta-Analysis |
| Zdroj: | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology, Vol 12 (2020) |
| ISSN: | 1758-8340 |
| Popis: | Background: Immune-related adverse events (irAEs) are common during immune checkpoint inhibitor (ICI) treatment and reported to be associated with good survival. This study evaluated the association between onset timing of irAEs and survival of cancer patients treated with ICIs. Methods: Databases including PubMed, Embase, and the Cochrane library were systematically searched to retrieve clinical studies assessing the relationship between irAEs and survival in cancer patients with ICIs. The overall response rate for treatment response and hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were calculated using RevMan 5.3. Subgroup analysis in terms of cancer type, ICIs type, region, specific irAEs, accordingly. Results: A total of 34 studies were included. The HRs for OS and PFS in cancer patients with versus without irAEs were 0.57 [95% confidence interval (CI): 0.44, 0.74; p 12 weeks, HROS = 1.08; 95% CI: 0.89, 1.30; p = 0.46). Conclusion: Our findings suggest that the occurrence of irAEs could be a prognostic factor for cancer patients who were treated with ICIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|